Top 10 Companies in the Pharmaceutical Hydrocolloids Market (2026): Market Leaders Powering Global Pharma

MARKET INSIGHTS

Global pharmaceutical hydrocolloids market size was valued at USD 376 million in 2024 and is projected to grow from USD 401 million in 2025 to USD 574 million by 2031, exhibiting a CAGR of 6.4% during the forecast period.

Pharmaceutical hydrocolloids are water‑soluble polymers derived from natural sources that form viscous solutions or gels when hydrated. These functional ingredients play critical roles in drug formulation as stabilizers, thickeners, binders, and controlled‑release agents. Major product segments include seaweed hydrocolloids (carrageenan, agar), plant‑derived gums (arabic gum, pectin), microbial polysaccharides (xanthan gum), and gelatin.

The market growth is driven by expanding pharmaceutical production volumes (Global pharmaceutical market reached USD 1.47 trillion in 2022) and increasing demand for novel drug delivery systems. However, stringent regulatory requirements for excipient approval and fluctuating raw material costs present challenges. Leading players like DuPont and Cargill are investing in R&D to develop multifunctional hydrocolloid systems for next‑generation formulations, particularly in oral solid dosage forms which dominate the pharmaceutical sector.

Pharmaceutical Hydrocolloids Market – View in Detailed Research Report

Top 10 Companies in the Pharmaceutical Hydrocolloids Market (2026)

10️⃣ 1. DuPont de Nemours, Inc.

Headquarters: Wilmington, Delaware, USA
Key Offering: Seaweed hydrocolloids, xanthan gum, specialized pharmaceutical‑grade excipients

DuPont’s extensive portfolio spans carrageenan, alginate, and high‑purity xanthan gum, positioning it as a primary supplier for oral solid dosage and controlled‑release applications. Recent investments focus on hybrid hydrocolloid blends that combine viscosity control with protein stabilization for biologic formulations.

Sustainability and Growth Initiatives:

• Expansion of the nutrition division to integrate plant‑based excipients
• Investment in bio‑industrial facilities to reduce carbon footprint
• Partnerships with academic centers for next‑generation polymer chemistry

9️⃣ 2. Cargill, Incorporated

Headquarters: Chicago, Illinois, USA
Key Offering: Xanthan gum, gellan gum, and specialty seaweed hydrocolloids

Cargill’s R&D pipeline targets high‑viscosity matrices that enhance drug stability while enabling low‑dose delivery. The company’s global sourcing network mitigates raw‑material volatility, a critical advantage in a market where supply disruptions can affect batch consistency.

Sustainability and Growth Initiatives:

• Strategic acquisitions in bio‑industrial applications to broaden excipient portfolio
• Implementation of closed‑loop manufacturing processes to cut waste
• Collaboration with regulatory bodies to streamline excipient approval pathways

8️⃣ 3. CP Kelco

Headquarters: Wilmington, Delaware, USA
Key Offering: Gellan gum, carrageenan, and specialty binding agents

CP Kelco’s recent launch of gellan gum for controlled drug release showcases its focus on functional differentiation. The company leverages proprietary processing techniques to achieve consistent rheological properties, essential for precision dosage forms.

Sustainability and Growth Initiatives:

• Investment in renewable feedstock sourcing for seaweed derivatives
• Development of low‑energy drying processes to reduce emissions
• Partnerships with pharmaceutical manufacturers to co‑create tailored excipients

7️⃣ 4. Ingredion Incorporated

Headquarters: Chicago, Illinois, USA
Key Offering: Modified starches, arabic gum, and specialty binders

Ingredion’s collaboration with Asian manufacturers expands its reach in emerging markets. The company’s focus on functional modifications of starches supports the growing demand for cost‑effective excipients in generic drug production.

Sustainability and Growth Initiatives:

• Strategic alliances to secure sustainable raw‑material supply chains
• Investment in carbon‑neutral production facilities
• R&D into biodegradable excipient alternatives for eco‑friendly formulations

6️⃣ 5. Kerry Group

Headquarters: Tralee, Ireland
Key Offering: Seaweed hydrocolloids, pectin, and specialty gums

Kerry’s 2023 announcement of a carbon‑neutral hydrocolloid production facility in Belgium signals a commitment to green manufacturing. This move aligns with pharmaceutical clients’ increasing emphasis on sustainable supply chains.

Sustainability and Growth Initiatives:

• Carbon‑neutral production plant in Belgium
• Investment in renewable energy for manufacturing sites
• Development of eco‑friendly packaging solutions for excipient products

5️⃣ 6. Royal DSM

Headquarters: Heerlen, Netherlands
Key Offering: Plant‑based hydrocolloids, specialty gums, and high‑purity cellulose derivatives

Royal DSM’s focus on sustainable production and product innovation positions it as a leader in clean‑label excipients. The company’s collaborations with pharmaceutical firms aim to deliver high‑performance, low‑environmental‑impact excipients.

Sustainability and Growth Initiatives:

• Carbon‑neutral manufacturing across key facilities
• Partnerships with biotech firms to develop protein‑stabilizing excipients
• Investment in life‑cycle assessment to optimize product sustainability

4️⃣ 7. Ashland Global Holdings Inc.

Headquarters: Waltham, Massachusetts, USA
Key Offering: Gelatin, modified starches, and specialty gums

Ashland’s expertise in gelatin and starch derivatives supports a wide range of dosage forms. The company’s focus on quality and regulatory compliance ensures consistent performance in high‑standard pharmaceutical applications.

Sustainability and Growth Initiatives:

• Implementation of sustainable sourcing practices for animal‑derived gelatin
• Investment in energy‑efficient processing technologies
• Collaboration with global manufacturers to develop tailored excipients

3️⃣ 8. FMC Corporation

Headquarters: St. Louis, Missouri, USA
Key Offering: Modified starches, arabic gum, and specialty binders

FMC’s global footprint and focus on functional excipient development support the expanding demand for cost‑effective and high‑performance formulations in the pharmaceutical sector.

Sustainability and Growth Initiatives:

• Investment in renewable feedstocks for starch production
• Partnerships with pharmaceutical companies to co‑develop excipient solutions
• Implementation of waste‑reduction programs across manufacturing sites

2️⃣ 9. Dow Chemical Company

Headquarters: Midland, Michigan, USA
Key Offering: Hydrocolloids for controlled release, binders, and stabilizers

Dow’s focus on advanced polymer chemistry enables the creation of excipients that meet stringent regulatory standards while offering performance advantages for complex drug products.

Sustainability and Growth Initiatives:

• Investment in green chemistry to reduce solvent usage
• Partnerships with pharma firms to develop low‑toxicity excipients
• Implementation of circular economy practices in manufacturing

1️⃣ 10. BASF

Headquarters: Ludwigshafen, Germany
Key Offering: Advanced polymer excipients, specialty gums, and high‑purity cellulose derivatives

BASF’s R&D pipeline focuses on excipients that enhance drug stability and bioavailability, supporting the development of next‑generation therapeutics.

Sustainability and Growth Initiatives:

• Investment in renewable energy for production facilities
• Development of biodegradable excipient alternatives
• Collaboration with regulatory agencies to streamline approval processes

Download FREE Sample Report

Get Full Report

Outlook: The Future of Pharmaceutical Hydrocolloids

In the next decade, the pharmaceutical hydrocolloids market will be shaped by a convergence of regulatory tightening, supply‑chain resilience, and innovation in drug delivery. Companies that invest in sustainable sourcing, advanced polymer chemistry, and strategic partnerships will gain a competitive edge. The expanding biologics and biosimilars landscape, coupled with the rise of 3D printing in pharma, will create new demand corridors that reward agility and technical expertise.

Key Trends Shaping the Market

• Shift toward plant‑based, clean‑label excipients to meet consumer and regulatory expectations
• Growth of specialty hydrocolloids for biologic stabilization and controlled‑release systems
• Adoption of additive manufacturing techniques requiring rheologically tailored excipients
• Increased focus on supply‑chain transparency and resilience to mitigate raw‑material volatility
• Emphasis on circular economy principles across production and packaging stages